Pasithea Therapeutics Corp. — Form 8-K Summary
Business context and reporting period
Pasithea Therapeutics Corp. filed a Form 8-K dated March 10, 2023, under Item 7.01 (Regulation FD). The filing is a corporate disclosure rather than a quarterly or annual financial report. Pasithea is incorporated in Delaware and its common stock and warrants trade on Nasdaq under the symbols KTTA and KTTAW.
Financial metrics and liquidity
The filing does not provide revenue, profit, cash flow, margins, debt, cash balances, or other financial metrics.
Material changes versus the prior comparable period
The filing does not report operating or financial changes versus a prior period. Pasithea confirmed that it does not hold deposits or securities, maintain accounts at, or have any other banking relationship with Silicon Valley Bank.
Guidance, risks, contingencies, and unusual items
The principal disclosure addresses potential exposure to Silicon Valley Bank. The company states that it has no such relationship. No guidance, business outlook, material contingencies, or unusual financial items are provided.
Important facts to verify
- Verify the company’s banking relationships and whether they changed after the filing date.
- Review subsequent filings for any liquidity, financing, cash-management, or banking updates.
- Consult the company’s latest periodic report for financial results, cash resources, debt, and going-concern disclosures.